Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 2457620, 6 pages
Clinical Study

Autologous Platelet-Rich Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome

1Division of Ophthalmology, School of Medicine, Universidad Miguel Hernández, Alicante, Spain
2Refractive Surgery Department, VISSUM, Alicante, Spain
3Research & Development Department and Cornea and Ocular Surface Department, VISSUM, Alicante, Spain
4Division of Ophthalmology, Universidad Miguel Hernández, Alicante, Spain
5Ophthalmology Department, Faculty of Medicine, Minia University, Minia, Egypt
6Research & Development Department, VISSUM, Alicante, Spain

Correspondence should be addressed to Jorge L. Alio; moc.mussiv@oilalj

Received 19 June 2017; Revised 5 September 2017; Accepted 16 October 2017; Published 12 December 2017

Academic Editor: David P. Piñero

Copyright © 2017 Jorge L. Alio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. To evaluate the efficacy of autologous platelet-rich plasma (E-PRP) eye drops for the treatment of chronic ocular surface syndrome (OSS) following laser in situ keratomileusis (LASIK). Methods. This prospective interventional consecutive clinical study include 156 eyes of 80 patients affected by post-LASIK chronic OSS who were treated with autologous E-PRP 6 times a day as monotherapy for 6 weeks. Results. Dry eye symptoms improved in 85% of the cases. A decrease in at least one quadrant to total disappearance on CFS was observed in 89.6% of the patients who had positive CFS before treatment. Three eyes presented severe punctate keratitis (1.9%) at baseline, all of which healed completely. Conjunctival hyperemia improved in 93.3% of the patients with previous signs of ocular surface inflammation. There was a significant improvement in logMAR CDVA from 0.14 ± 0.19 to 0.06 ± 0.12 (), and 74 (71.4%) eyes improved at least 1 line in CDVA. Conclusion. Monotherapy with autologous E-PRP is a well-tolerated, safe, and effective treatment for the management of post-LASIK ocular surface syndrome. Precis. Monotherapy with autologous platelet-rich plasma eye drops has been shown to be an adequate option for the treatment of post-LASIK chronic ocular surface syndrome. This trial is registered with NCT03322917.